AgPlus’s mission is to be recognised as a market leader in innovative Point of Care diagnosis, matching each patient’s critical condition to the right treatment at the right time.
Whilst COVID-19 is the prevalent pandemic right now another global problem we are potentially facing is the antimicrobial resistance. 50% of antibiotics are mis-prescribed, and there has been no new antibiotics developed since the late 1980’s, so AgPlus is developing a diagnostic assay that will differentiate between bacterial and viral infection and thus allow targeted treatment of antibiotics.
The STI Research and Development team have been working closely with AgPlus since 2019 to transition their current lab reader to the Agilis™ PoC reader. AgPlus CEO, Fiona Marshall, said: “We are on track with STI to receive our first prototypes in July for our clinical verification studies, with a challenging but achievable timeline of end 2020 to get our first of industrial designs and design for manufacture pack, so that we can transition to manufacture at STI, with clinical validation, and regulatory submission following in Q1 2021”.
Fiona added: “STI’s innovative approach to finding solutions has meant the progress towards the prototypes has been faster than anticipated. Their professional manner and open discussion with all parties has been refreshing and greatly appreciated by AgPlus. The early communication from the manufacturing, commercial and quality team has also been extremely positive and open. This is a project that will have huge impact in healthcare and people’s lives in the near future and AgPlus is delighted to be working with STI as our key partner to deliver the Agilis™ reader.”